E-MEXP-3807
Ontology highlight
ABSTRACT:
DISEASE(S): Acute Graft Versus Host Disease,Normal
PROVIDER: E-MEXP-3807 | ExpressionAtlas | 2015-10-22
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-MEXP-3807-analysis-methods.tsv | Tabular | |||
| E-MEXP-3807-atlasExperimentSummary.Rdata | Rdata | |||
| E-MEXP-3807-configuration.xml | Xml | |||
| E-MEXP-3807-percentile-ranks.tsv | Tabular | |||
| E-MEXP-3807.condensed-sdrf.tsv | Tabular |
Items per page: 5 1 - 5 of 52 |
Similar Datasets
Project description:Mice received TBI and allogeneic bone marrow transplantation. One group without and one group with T cells. On day 14 after transplantation mice were sacrificed and the intestinal tract was isolated. RNA was isolated from the intestinal tract of the two experimental groups.
2013-01-16 | E-MEXP-3807 | biostudies-arrayexpress
Project description:Current therapies for metastatic colorectal cancer only prolong life for approximately 2 years. A more innovative therapy that prolongs life significantly or even cures is needed. Bone marrow transplantation is a curative therapy for patients with leukemias and lymphomas. Tumor eradication in the case of transplantation of the patient’s own marrow (autologous transplantation) is based on the intensive chemotherapy and/or radiotherapy used for conditioning. Tumor eradication in the case of transplantation using the marrow of a normal donor is based on both tumor reduction from conditioning and the immune elimination of tumor cells by T cells in the donor transplant that recognize the foreign tissue antigens expressed by the tumor cells and kill these cells. The use of bone marrow transplantation to treat tumors other than leukemia and lymphoma has been limited, and studies of transplantation of the patient’s own marrow for the treatment of advanced /metastatic breast cancer have not conclusively shown benefit beyond conventional therapy.
Recently, the Strober lab developed a preclinical model that effectively treated colon cancer in mice by combining immunotherapy and autologous bone marrow transplantation in order to markedly augment the anti-tumor potency of immunotherapy. They used the CT26 colon cancer as the therapeutic target either as a single subcutaneous tumor nodule, as a disseminated tumor in the lungs and peritoneum, or as a metastatic tumor in the liver depending on the route of administration of the tumor cells in BALB/c mice. Mice were vaccinated mice with established primary tumors or disseminated/ metastatic disease with irradiated tumor cells mixed with the adjuvant CpG, and found that vaccination alone had no effect on tumor growth. Similarly radiation conditioning of tumor bearing hosts followed by transplantation of bone marrow and spleen cells or purified T cells and hematopoietic stem cells from unvaccinated donors of the same strain had no effect. In contrast, radiation conditioning of mice followed by transplantation of hematopoietic and immune cells from donors of the same strain vaccinated with tumor cells and CpG cured almost all subcutaneous primary as well as disseminated and metastatic tumors in the hosts. A similar result was obtained after autologous transplantation of hematopoietic and immune cells from tumor bearing mice that had been vaccinated after tumor establishment. Investigation of tumor infiltrating cells showed that the injected donor T cells do not accumulate in the tumors unless the host has been irradiated before injection.
Based on this model, we have assembled a team of Stanford University faculty members with expertise in gastrointestinal cancers, immunotherapy, radiation oncology, and bone marrow transplantation in the Departments of Medicine and Pathology to translate the preclinical findings into a Phase I safety and feasibility clinical study for the treatment of 10 patients with metastatic colorectal cancer. Resected tumor cells will be irradiated and mixed with CpG to create a vaccine. Patients will receive subcutaneous vaccination at weeks 1 and 2 after resection. Six weeks later, immune T cells and then G-CSF "mobilized" purified blood progenitor cells will be harvested from the blood and cryopreserved. If needed patients will receive chemotherapy for tumor reduction. When disease is controlled off chemotherapy, patients will receive a conditioning regimen of fludarabine (30mg/m2 daily x 3 days) followed by intensive fractionated total body irradiation. The dose of fTBI will be escalated using a 3+3 design to ensure safety and will range from 400 to 800 gray. The patient will then undergo hematopoietic and immune cell rescue. They will undergo a third vaccination within 7-14 days after transplant. Thereafter, serial monitoring of tumor burden will continue.
Immune monitoring will occur before and after vaccination as well as after transplantation. Tests will include in vitro anti-tumor immune responses of T cells (proliferation, cytotoxicity, cytokine secretion etc.) to stimulation with whole tumor cells and tumor cell lysates pulsed on to antigen presenting cells, anti-tumor antibody responses, and immune reconstitution after transplantation.
| 2063196 | ecrin-mdr-crc
Project description:We cultured bone marrow derived dendritic cells from WT and CD11c KO mice. Then, a group of bone marrow dendritic cells were stimulated with LPS overnight. We obtained bone marrow derived dendritic cells with or without LPS stimulation and analyzed proteomics profiles.
2024-01-26 | PXD048907 |
Project description:Untargeted metabolites of supernatant of wild-type and Nlrp3-/- bone marrow-derived macrophages without stimulation or with 4 hours of LPS preconditioning and subsequently 30 min of ATP stimulation.
2025-07-08 | MTBLS12152 | MetaboLights
Project description:Bone marrow derived macrophages from wild type and STAT6(-/-) mice after 24 hours stimulation using IL4/IL13 (10ng/mL) (in replicates N = 3 per group). Cells without stimulation refer as controls.
2026-03-18 | GSE297550 | GEO
Project description:<p>We are studying the natural history, pathogenesis and treatment of patients with WHIM syndrome, an immunodeficiency disorder characterized by warts, hypogammaglobulinemia, recurrent infections and neutropenia usually due to autosomal dominant gain-of-function mutations in chemokine receptor <i>CXCR4</i>. We have identified a patient born with WHIM syndrome and the WHIM mutation <i>CXCR4<sup>R334X</sup></i> who has been disease-free for 20 years and who lacks <i>CXCR4<sup>R334X</sup></i> in myeloid cells, the cells that drive disease manifestations. She is a genetic and hematopoietic mosaic, since she still has the mutation in lymphoid cells and non-hematopoietic cells. Cytogenetics and microarray analysis revealed that the mechanism of loss of the mutation was deletion of the mutant allele from one copy of chromosome 2. Whole genome sequencing of patient neutrophil and skin fibroblast genomic DNA revealed that the mechanism of deletion was chromothripsis, a process of chromosome shattering resulting in deletions and rearrangements of the non-deleted chromosomal segments. In the patient, this process evidently occurred in a single hematopoietic stem cell (HSC), resulting in deletion of the disease allele <i>CXCR4<sup>R334X</sup></i> and one copy of 163 other genes on chromosome 2. This HSC evidently acquired a growth advantage and repopulated the HSC population and the myeloid lineage. Consistent with this, studies using gene targeted mice in competitive bone marrow transplantation experiments revealed that selective <i>Cxcr4</i> haploinsufficiency (inactivation of one copy of <i>Cxcr4</i> and not of any other genes) was sufficient to confer a strong engraftment advantage over bone marrow cells from wild type mice as well as bone marrow cells from a mouse model of WHIM syndrome. These results suggest that <i>CXCR4</i> knockdown may be a useful strategy to enhance bone marrow engraftment in the absence of toxic bone marrow conditioning regimens.</p>
| phs000856 | dbGaP
Project description:Single-cell RNA sequencing analysis of RUNX1-RUNX1T1(9a) transformed c-kit positive cells with (Kat2a WT) and without Kat2a (Kat2a NULL). Lineage negative bone marrow cells were collected from Kat2a fl/fl Mx1-Cre-/- and Kat2a fl/fl Mx1-Cre +/- animals after pIpC treatment and transduced with RUNX1-RUNX1T1(9a) expressing retrovirus (reported by GFP expression). Cells were injected into irradiated C57BL6 mice and GFP positive c-Kit positive bone marrow cells collected 2 and 4 months after transplantation. Cells were processed for single-cell RNA sequencing library preparation (10X chromium single cell) and next gene sequencing following 10X genomics v2 protocol.
2022-08-24 | E-MTAB-10853 | biostudies-arrayexpress
Project description:<p>Bone regeneration requires spatiotemporal coordination of immune modulation, stem cell recruitment, angiogenesis, and osteogenesis, yet most scaffolds lack sequential control across healing phases. We develop a near-infrared (NIR)-responsive therapeutic platform that integrates clinically available irradiation with an engineered 3D radially aligned nanofiber scaffold functionalized with black phosphorus (BP) and a bone marrow mesenchymal stem cell (BMSC)-targeting aptamer (Apt19S). NIR photothermal stimulation accelerates BP degradation, releasing phosphate ions and activating a heat-shock program to promote macrophage polarization, endogenous MSC homing, neovascularization, and osteogenic differentiation. Metabolomics reveals cooperative regulation of HSP-linked signaling and lipid metabolism. In a rat critical-size calvarial defect, the platform achieves robust bone regeneration without exogenous cells or growth factors. The system is simple, structurally tunable, and shape-customizable, providing a clinically translatable and modular framework for spatiotemporal microenvironment programming in bone and other regenerative settings.</p>
2026-03-04 | MTBLS13974 | MetaboLights
Project description:RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.
| 2004880 | ecrin-mdr-crc
Project description:To identify factors that could explain why mice transplanted with Vim deficient bone marrow display decreased atherosclerosis despite increased inflammation, we performed global gene expression profiling of bone-marrow derived macrophages from vimentin-deficient or wild-type littermates on C57BL/6 background. We elucidated the role of vimentin in atherogenic low-density receptorâ deficient mice after bone marrow transplantation from vimentin-deficient mice.
2016-03-11 | E-GEOD-63653 | biostudies-arrayexpress